| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
HIV-1/2 nucleotide reverse transcriptase
(R,1R)-Tenofovir amibufenamide targets the viral reverse transcriptase enzyme after being converted to its active form, tenofovir. Tenofovir is a nucleotide analog that, after intracellular phosphorylation to tenofovir diphosphate, competes with the natural substrate deoxyadenosine triphosphate for incorporation into the growing viral DNA chain. Once incorporated, it acts as a chain terminator, halting viral DNA synthesis and inhibiting viral replication. This mechanism is effective against both HIV and HBV. The compound is a prodrug that is activated in the body to release tenofovir. |
|---|---|
| ln Vitro |
In vitro, (R,1R)-Tenofovir amibufenamide is used as a tenofovir prodrug for research purposes. It exhibits antiviral activity against viruses that are susceptible to tenofovir, such as HIV and HBV. The compound's activity is attributed to its conversion to tenofovir, which then inhibits the viral reverse transcriptase. It is used in cell-based assays to study the efficacy and pharmacology of tenofovir prodrugs. The compound's purity is typically high (e.g., 98.87%), making it suitable for research applications.
|
| ln Vivo |
In vivo, (R,1R)-Tenofovir amibufenamide is an orally active prodrug that delivers tenofovir. It is designed to improve the oral bioavailability and pharmacokinetic profile of tenofovir. The compound is metabolized in the body to release tenofovir, which then exerts its antiviral activity. It is used in preclinical and clinical research to study the efficacy and safety of tenofovir prodrugs for the treatment of HIV and HBV infections. The compound's in vivo activity is characterized by its ability to inhibit viral replication after oral administration.
|
| Enzyme Assay |
In vitro enzyme assays for (R,1R)-Tenofovir amibufenamide are not typically performed directly, as the compound is a prodrug. Instead, its activity is measured after conversion to tenofovir. The active form, tenofovir diphosphate, is assayed for its ability to inhibit the reverse transcriptase enzyme. In these assays, the enzyme is incubated with a template-primer, nucleotides, and varying concentrations of tenofovir diphosphate. The incorporation of the nucleotide analog into the DNA chain is measured to determine the inhibitory activity. The compound's prodrug nature means that its activity is assessed through its metabolites in cellular or in vivo systems.
|
| Cell Assay |
In vitro cell-based assays for (R,1R)-Tenofovir amibufenamide are performed in cell lines susceptible to HIV or HBV infection. Cells are infected with the virus and treated with varying concentrations of the compound. The antiviral activity is assessed by measuring the reduction in viral replication, typically by quantifying viral DNA or RNA levels using qPCR or by measuring viral protein expression. The compound's efficacy is determined by calculating the half-maximal effective concentration (EC50). Cytotoxicity is assessed by measuring cell viability in uninfected cells treated with the compound. The compound is typically dissolved in DMSO and diluted in cell culture medium.
|
| Animal Protocol |
Specific in vivo animal experiment protocols for (R,1R)-Tenofovir amibufenamide are not detailed in the available literature. However, as an orally active prodrug, it would typically be administered orally to animal models of HIV or HBV infection. Dosing regimens would be designed to achieve therapeutic concentrations of tenofovir in the plasma. The compound's efficacy would be assessed by measuring viral load in the blood. Pharmacokinetic studies would be conducted to determine the compound's absorption, distribution, metabolism, and excretion. The route of administration would be oral, and the dosing frequency would depend on the compound's half-life.
|
| ADME/Pharmacokinetics |
(R,1R)-Tenofovir amibufenamide is a prodrug of tenofovir, designed for oral administration to improve bioavailability. After oral administration, it is absorbed and converted to tenofovir, which is then phosphorylated intracellularly to the active tenofovir diphosphate. The pharmacokinetic properties of the compound are characterized by its absorption, conversion to tenofovir, and the subsequent distribution and elimination of tenofovir. The compound's oral bioavailability is a key feature of its design. For long-term storage, the compound is kept as a powder under appropriate conditions.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for (R,1R)-Tenofovir amibufenamide are not provided in the available sources. As a prodrug of tenofovir, its toxicity profile is likely related to that of tenofovir. Tenofovir is generally well-tolerated, but it can cause renal toxicity and bone mineral density loss with long-term use. As a research chemical, its safety profile in humans has not been fully established. The compound is classified as a research reagent and is not for therapeutic or veterinary use. Standard laboratory safety precautions should be followed when handling this compound. Its purity is typically ≥98%.
|
| References | |
| Additional Infomation |
See also: Tenofovir disoproxil fumarate (note moved to).
(R,1R)-Tenofovir amibufenamide, also known as (R,1R)-HS-10234, is a prodrug of the nucleotide reverse transcriptase inhibitor tenofovir. It is designed for oral administration to improve the bioavailability of tenofovir. Tenofovir is a nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) used in the treatment of HIV and hepatitis B virus (HBV) infections. As a prodrug, (R,1R)-Tenofovir amibufenamide is converted to the active form, tenofovir, in the body, where it inhibits viral reverse transcriptase. The compound has antiviral activity and is used in research to study the pharmacology of tenofovir prodrugs. It is intended for research use only and is not for human consumption. |
| Molecular Formula |
C22H31N6O5P
|
|---|---|
| Molecular Weight |
490.492505311966
|
| Exact Mass |
490.209
|
| CAS # |
1571076-37-3
|
| Related CAS # |
Tenofovir amibufenamide;1571076-26-0;(1R)-Tenofovir amibufenamide;1571076-15-7
|
| PubChem CID |
73335908
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
34
|
| Complexity |
720
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(NC(C)(C)C(=O)OC(C)C)OC3=CC=CC=C3
|
| InChi Key |
ORHSFGJQGPUCRR-LXAPUOBYSA-N
|
| InChi Code |
InChI=1S/C22H31N6O5P/c1-15(2)32-21(29)22(4,5)27-34(30,33-17-9-7-6-8-10-17)14-31-16(3)11-28-13-26-18-19(23)24-12-25-20(18)28/h6-10,12-13,15-16H,11,14H2,1-5H3,(H,27,30)(H2,23,24,25)/t16-,34?/m1/s1
|
| Chemical Name |
propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]-2-methylpropanoate
|
| Synonyms |
(1R)-Tenofovir amibufenamide; Tenofovir amibufenamide; 1571076-15-7; 1571076-37-3; (R,1R)-Tenofovir amibufenamide; 1571076-26-0; SCHEMBL16882600;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~200 mg/mL (~407.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0388 mL | 10.1939 mL | 20.3878 mL | |
| 5 mM | 0.4078 mL | 2.0388 mL | 4.0776 mL | |
| 10 mM | 0.2039 mL | 1.0194 mL | 2.0388 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
